ZA201007976B - Anti-pirb antibodies - Google Patents
Anti-pirb antibodiesInfo
- Publication number
- ZA201007976B ZA201007976B ZA2010/07976A ZA201007976A ZA201007976B ZA 201007976 B ZA201007976 B ZA 201007976B ZA 2010/07976 A ZA2010/07976 A ZA 2010/07976A ZA 201007976 A ZA201007976 A ZA 201007976A ZA 201007976 B ZA201007976 B ZA 201007976B
- Authority
- ZA
- South Africa
- Prior art keywords
- pirb
- antibodies
- pirb antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5294908P | 2008-05-13 | 2008-05-13 | |
| US12/208,883 US20100047232A1 (en) | 2006-11-14 | 2008-09-11 | Modulators of neuronal regeneration |
| US12/316,130 US20090232794A1 (en) | 2007-12-11 | 2008-12-09 | Modulators of neuronal regeneration |
| PCT/US2009/043757 WO2009140361A1 (en) | 2008-05-13 | 2009-05-13 | ANTI-PirB ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201007976B true ZA201007976B (en) | 2012-02-29 |
Family
ID=41319035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/07976A ZA201007976B (en) | 2008-05-13 | 2010-11-08 | Anti-pirb antibodies |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2291405A1 (es) |
| JP (1) | JP2011523359A (es) |
| KR (1) | KR20110011676A (es) |
| CN (1) | CN102089327A (es) |
| AR (1) | AR071777A1 (es) |
| AU (1) | AU2009246443A1 (es) |
| BR (1) | BRPI0912769A2 (es) |
| CA (1) | CA2723430A1 (es) |
| IL (1) | IL209129A0 (es) |
| MX (1) | MX2010012299A (es) |
| PE (1) | PE20091969A1 (es) |
| RU (1) | RU2010150754A (es) |
| TW (1) | TW200950808A (es) |
| WO (1) | WO2009140361A1 (es) |
| ZA (1) | ZA201007976B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| AU2011207253B2 (en) | 2010-01-20 | 2015-02-12 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
| ES2655077T3 (es) * | 2012-04-17 | 2018-02-16 | Mayo Foundation For Medical Education And Research | Anticuerpos humanos y secuencias de unión específicos del mismo para uso en accidente cerebrovascular e isquemia y condiciones isquémicas |
| CN103130898B (zh) * | 2013-01-28 | 2014-03-26 | 中国人民解放军第四军医大学 | Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用 |
| EP4219559A3 (en) | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| SG11202100096XA (en) | 2018-07-09 | 2021-02-25 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| CN109439661B (zh) * | 2018-10-22 | 2020-10-23 | 西安医学院 | 抑制pirB表达的短发卡shRNA、慢病毒及其应用 |
| EP4071172A4 (en) | 2019-12-23 | 2023-10-18 | Lg Chem, Ltd. | ANTI-LILRB1 ANTIBODIES AND ITS USES |
| PE20221894A1 (es) | 2020-05-01 | 2022-12-13 | Ngm Biopharmaceuticals Inc | Agentes de union a ilt y metodos para su uso |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050238643A1 (en) * | 2001-11-14 | 2005-10-27 | Arm Jonathan P | Modulation of lir function to treat rheumatoid arthritis |
| CA2637786A1 (en) * | 2006-01-23 | 2007-08-16 | President And Fellows Of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
-
2009
- 2009-05-13 EP EP09747445A patent/EP2291405A1/en not_active Withdrawn
- 2009-05-13 MX MX2010012299A patent/MX2010012299A/es active IP Right Grant
- 2009-05-13 KR KR1020107027786A patent/KR20110011676A/ko not_active Withdrawn
- 2009-05-13 BR BRPI0912769A patent/BRPI0912769A2/pt not_active IP Right Cessation
- 2009-05-13 PE PE2009000673A patent/PE20091969A1/es not_active Application Discontinuation
- 2009-05-13 TW TW098115945A patent/TW200950808A/zh unknown
- 2009-05-13 CN CN2009801265242A patent/CN102089327A/zh active Pending
- 2009-05-13 WO PCT/US2009/043757 patent/WO2009140361A1/en not_active Ceased
- 2009-05-13 JP JP2011509642A patent/JP2011523359A/ja active Pending
- 2009-05-13 CA CA2723430A patent/CA2723430A1/en not_active Abandoned
- 2009-05-13 RU RU2010150754/10A patent/RU2010150754A/ru not_active Application Discontinuation
- 2009-05-13 AU AU2009246443A patent/AU2009246443A1/en not_active Abandoned
- 2009-05-13 AR ARP090101723A patent/AR071777A1/es not_active Application Discontinuation
-
2010
- 2010-11-04 IL IL209129A patent/IL209129A0/en unknown
- 2010-11-08 ZA ZA2010/07976A patent/ZA201007976B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR071777A1 (es) | 2010-07-14 |
| JP2011523359A (ja) | 2011-08-11 |
| RU2010150754A (ru) | 2012-06-20 |
| CN102089327A (zh) | 2011-06-08 |
| MX2010012299A (es) | 2010-12-06 |
| KR20110011676A (ko) | 2011-02-08 |
| WO2009140361A1 (en) | 2009-11-19 |
| PE20091969A1 (es) | 2010-01-15 |
| CA2723430A1 (en) | 2009-11-19 |
| BRPI0912769A2 (pt) | 2015-10-13 |
| AU2009246443A1 (en) | 2009-11-19 |
| IL209129A0 (en) | 2011-01-31 |
| TW200950808A (en) | 2009-12-16 |
| EP2291405A1 (en) | 2011-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0821100D0 (en) | Antibodies | |
| ZA201102119B (en) | Improved antibody libraies | |
| GB0708002D0 (en) | Antibodies | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
| IL212701A0 (en) | Improved anti-cd19 antibodies | |
| ZA201101970B (en) | Multispecific antibodies | |
| PL2146745T3 (pl) | Pięcioswoiste przeciwciało | |
| ZA201100300B (en) | Anti-cd5 antibodies | |
| ZA201008024B (en) | Anti-flt3 antibodies | |
| SI2200700T1 (sl) | Nova protitelesa | |
| SG10201401331TA (en) | Anti-siglec-15 antibody | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| IL207581A0 (en) | Anti-tyrp1 antibodies | |
| GB0718737D0 (en) | Antibodies | |
| IL205073A0 (en) | Anti-bst2 antibody | |
| GB0702888D0 (en) | Novel Antibodies | |
| GB0920324D0 (en) | Antibodies | |
| GB0905972D0 (en) | Antibodies against IL-17BR | |
| ZA201007976B (en) | Anti-pirb antibodies | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| GB0818356D0 (en) | Antibodies | |
| GB2473934B (en) | Anti-VEEV antibody |